This 3 week BCG maintenance schedule alone has reduced disease progression and mortality in multicenter randomized clinical trials. In the new age of immuno-oncology patients with many types of cancer now benefit from immunotherapy, but currently these modern agents are prohibitively expensive for most...
Alternatively, there may be a lower risk of ADRD associated with earlier BCG vaccine treatment; the initiation and maintenance schedule of BCG vaccine treatment of bladder cancer is individualized, but treatments are more frequent nearer to the initial NMIBC diagnosis. A recent cohort study observed...
Non-surgical treatments for BCG-unresponsive high-risk non-muscle-invasive bladder cancer have been suboptimal, including repeated BCG induction and maintenance therapy, intravesical chemotherapy,and device-assisted therapies aimed at improving the efficacy of intravesical treatment.Until recently, only intrave...
T1, or Tis) and were treated with at least seven doses of BCG (five during induction and two during maintenance). Patients were also eligible if they were
For a patient to be considered BCG-unresponsive, they must have received ≥1 induction course (6 weeks) and one maintenance course (3 weeks) and either have refractory tumour (no disease-free interval) or have recurrence of high-grade tumour within 6 months of their last BCG exposure ...
When administered at full-dose in a maintenance schedule of 36 months, Bacillus Calmette-Guérin (BCG) immunotherapy reduces recurrence and progression of high risk non-muscle-invasive bladder cancer (NMIBC). However, many patients do not complete a full course of therapy due to its toxicity or ...
The sTn structurally related antigen was also evaluated for the first time in the context of bladder cancer. tumour free. All received intravesical instillation of BCG for 6 consecutive weeks (induction BCG scheme, iBCG) and 56.4% were submitted to maintenance BCG schedule (iBCG þ maintenance ...
Lamm DL (1995) BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol 27:2–8 PubMedGoogle Scholar Witjes JA, Fransen MPH, van der Meijden (1993) Use of maintenance intravesical bacillus Calmette-Guerin (BCG), with or without intradermal BCG, in patients with...
Optimal schedule of Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: A meta-analysis of comparative studies To explore the necessity of maintenance, efficacy of low-dose and superiority of various combination therapies of Bacillus Calmette-Guerin (BCG) in treatme... S Zhu,Y Tang,...
Farah NB,Ghanem R,Amr M.Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin(BCG)-RIVM strain:induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer(NMIBC)[J].BMC Urol,2014,14:11....